We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $335M
1-Year Est. Return 275.57%
This Fund
S&P 500
This Quarter Est. Return
+23.4%
1 Year Est. Return
+275.57%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$145M
AUM Growth
+$10.7M
Cap. Flow
+$7.44M
Cap. Flow %
5.12%
Top 10 Hldgs %
27.16%
Holding
316
New
137
Increased
28
Reduced
59
Closed
75

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$4.91M
2
EHC icon
Encompass Health
EHC
+$3.58M
3
IBIT icon
iShares Bitcoin Trust
IBIT
+$3.43M
4
AMGN icon
Amgen
AMGN
+$3.35M
5
LLY icon
Eli Lilly
LLY
+$2.53M

Sector Composition

Rank Sector Weight
1 Healthcare 48.9%
2 Financials 13.82%
3 Miscellaneous 11.7%
4 Technology 6.61%
5 Consumer Discretionary 5.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SAIL
26
SailPoint Inc
SAIL
$10.7B
$1.53M 1.05%
+69,161
New +$1.45M
EHAB
27
DELISTED
Enhabit
EHAB
$1.49M 1.02%
185,594
-20,389
-10% -$153K
INDV icon
28
Indivior Pharmaceuticals
INDV
$4.12B
$1.41M 0.97%
+58,409
New +$1.22M
BMY icon
29
Bristol-Myers Squibb
BMY
$136B
$1.34M 0.92%
+29,793
New +$1.39M
RBRK icon
30
Rubrik
RBRK
$19.4B
$1.32M 0.9%
+16,000
New +$1.38M
THC icon
31
Tenet Healthcare
THC
$21.3B
$1.31M 0.9%
6,456
-6,065
-48% -$1.08M
ASND icon
32
Ascendis Pharma A/S
ASND
$17.7B
$1.26M 0.86%
+6,330
New +$1.18M
BABA icon
33
Alibaba
BABA
$281B
$1.25M 0.86%
+7,000
New +$917K
NBIX icon
34
Neurocrine Biosciences
NBIX
$15.8B
$1.22M 0.84%
8,694
-12,931
-60% -$1.75M
HSAI
35
Hesai Group
HSAI
$2.97B
$1.21M 0.83%
+43,226
New +$1.06M
VKTX icon
36
Viking Therapeutics
VKTX
$4.07B
$1.17M 0.81%
44,578
-904
-2% -$27K
C icon
37
Citigroup
C
$231B
$1.15M 0.79%
11,366
-5,067
-31% -$481K
FBK icon
38
FB Financial Corp
FBK
$2.85B
$1.14M 0.78%
+20,455
New +$1.04M
SF
39
Stifel
SF
$12.3B
$1.13M 0.78%
14,999
+7,962
+113% +$596K
AX icon
40
Axos Financial
AX
$5.56B
$1.08M 0.74%
12,729
-6,052
-32% -$527K
INTC icon
41
Intel
INTC
$506B
$1.07M 0.74%
32,000
+22,000
+220% +$533K
ETHA
42
iShares Ethereum Trust ETF
ETHA
$8.32B
$1.05M 0.72%
33,218
-52,679
-61% -$1.56M
IMCR icon
43
Immunocore
IMCR
$1.86B
$1.04M 0.71%
28,615
+4,577
+19% +$156K
ALNY icon
44
Alnylam Pharmaceuticals
ALNY
$35.6B
$1.03M 0.71%
+2,252
New +$917K
HBM icon
45
Hudbay
HBM
$12.2B
$1.03M 0.71%
67,754
-55,398
-45% -$634K
HCA icon
46
HCA Healthcare
HCA
$87.7B
$1M 0.69%
+2,353
New +$912K
CFLT
47
DELISTED
Confluent
CFLT
$990K 0.68%
50,000
+30,000
+150% +$627K
CCB icon
48
Coastal Financial
CCB
$769M
$983K 0.68%
9,091
-7,341
-45% -$778K
NKTR icon
49
Nektar Therapeutics
NKTR
$2.53B
$983K 0.68%
+17,270
New +$572K
NWS icon
50
News Corp Class B
NWS
$18.2B
$951K 0.65%
+27,513
New +$929K

Similar funds

Persistent Asset Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Persistent Asset Partners held 316 positions worth $145M, up 7.9% from $135M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Persistent Asset Partners deployed $7.44M of net new capital in Q3 2025, opening 137 new positions and adding to 28 existing holdings. Its largest new stake was Centene: 229,544 shares worth $8.19M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 52% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was iShares Bitcoin Trust, an estimated $3.43M trimmed.

  • Persistent Asset Partners's largest Q3 2025 buy was Centene: 229,544 shares worth $8.19M.
  • Persistent Asset Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $3.17M increase.
  • Persistent Asset Partners's biggest Q3 2025 reduction was iShares Bitcoin Trust, cutting an estimated $3.43M.
  • Persistent Asset Partners fully exited Humana in Q3 2025, selling an estimated $4.91M.
  • Persistent Asset Partners's ten largest holdings make up 27% of its $145M portfolio in Q3 2025.
  • Persistent Asset Partners opened 137 new positions and closed 75 in Q3 2025.
  • Persistent Asset Partners's portfolio value rose 7.9% quarter-over-quarter to $145M.

Based on Persistent Asset Partners's 13F filing for Q3 2025, filed 10 Nov 2025.